These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17559842)

  • 1. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.
    Seifer DB; Maclaughlin DT
    Fertil Steril; 2007 Sep; 88(3):539-46. PubMed ID: 17559842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome.
    Siow Y; Kives S; Hertweck P; Perlman S; Fallat ME
    Fertil Steril; 2005 Oct; 84(4):938-44. PubMed ID: 16213847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome.
    Wang JG; Nakhuda GS; Guarnaccia MM; Sauer MV; Lobo RA
    Am J Obstet Gynecol; 2007 Jan; 196(1):77.e1-5. PubMed ID: 17240243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization.
    Nakhuda GS; Chu MC; Wang JG; Sauer MV; Lobo RA
    Fertil Steril; 2006 May; 85(5):1541-3. PubMed ID: 16566934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental expression and cellular distribution of Mullerian inhibiting substance in the primate ovary.
    Modi D; Bhartiya D; Puri C
    Reproduction; 2006 Sep; 132(3):443-53. PubMed ID: 16940285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
    Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB
    Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mullerian inhibiting substance in female reproduction.
    Nakhuda GS
    Curr Opin Obstet Gynecol; 2008 Jun; 20(3):257-64. PubMed ID: 18460940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?
    La Marca A; Volpe A
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):603-10. PubMed ID: 16712660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.
    Silberstein T; MacLaughlin DT; Shai I; Trimarchi JR; Lambert-Messerlian G; Seifer DB; Keefe DL; Blazar AS
    Hum Reprod; 2006 Jan; 21(1):159-63. PubMed ID: 16123085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
    Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
    Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.
    Lane AH; Lee MM; Fuller AF; Kehas DJ; Donahoe PK; MacLaughlin DT
    Gynecol Oncol; 1999 Apr; 73(1):51-5. PubMed ID: 10094880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-mullerian hormone and its role in the regulation of ovarian function. Review of the literature].
    Tsepelidis S; Demeestere I; Delbaere A; Gervy C; Englert Y
    Rev Med Brux; 2007; 28(3):165-71. PubMed ID: 17708472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
    Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
    Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Anti-Mullerian hormone and ovarian cancer.
    La Marca A; Volpe A
    Hum Reprod Update; 2007; 13(3):265-73. PubMed ID: 17213257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and ovarian Müllerian inhibiting substance, and their decline in reproductive aging.
    Yeh J; Kim B; Peresie J; Liang YJ; Arroyo A
    Fertil Steril; 2007 May; 87(5):1227-30. PubMed ID: 17222835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testicular anti-Müllerian hormone: history, genetics, regulation and clinical applications.
    Josso N; Picard JY; Rey R; di Clemente N
    Pediatr Endocrinol Rev; 2006 Jun; 3(4):347-58. PubMed ID: 16816803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Müllerian hormone and ovarian dysfunction.
    Broekmans FJ; Visser JA; Laven JS; Broer SL; Themmen AP; Fauser BC
    Trends Endocrinol Metab; 2008 Nov; 19(9):340-7. PubMed ID: 18805020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.
    La Marca A; Giulini S; Tirelli A; Bertucci E; Marsella T; Xella S; Volpe A
    Hum Reprod; 2007 Mar; 22(3):766-71. PubMed ID: 17071823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage.
    Yeh J; Kim B; Liang YJ; Peresie J
    Biochem Biophys Res Commun; 2006 Sep; 348(2):337-44. PubMed ID: 16875679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.